Bladder Cancer

For patients with cisplatin-ineligible bladder cancer, presurgical Padcev decreased the cancer stage without leading to delays in surgery.

The FDA has approved several treatments for patients with solid tumors. Here are five recently approved treatments.

A novel delivery system of gemcitabine called TAR-200 led to promising responses in certain patients with non-muscle-invasive bladder cancer.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer.

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

The survival benefit observed with Padcev plus Keytruda was “unlike anything we’d seen before” for advanced bladder cancer, according to an expert.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

Treatment with immune checkpoint inhibitors has improved survival outcomes for patients with metastatic bladder cancer, compared with chemotherapy.

Quality of life, sexual outcomes and self-image should be considered before choosing a treatment option for muscle-invasive bladder cancer, an expert said.

From Oliva Munn and Christine Brinkley discussing their cancer to Donnie Iris returning to the stage after his experience with the disease, here is what’s happening in the oncology space this week.

The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.

A phase 2 trial showed that Trodelvy plus Keytruda had a high response rate with lasting responses, emphasizing “potential additive or synergistic effects,” an expert said.

Anktiva boosted responses to BCG treatment without affecting quality of life, research showed.

Treatment for muscle-invasive bladder cancer called dose-dense MVAC did not improve survival compared with chemotherapy alone, although one drug in the combination faces a shortage.

I had a friend who was diagnosed with the same bladder cancer as me, though our experiences were extremely different.

Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said.

The Food and Drug Administration will speed up their review of Enhertu for previously treated patients with certain HER2-positive solid tumors.

Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.

Postsurgical Keytruda improved disease-free survival — but not overall survival — in patients with locally advanced, muscle-invasive bladder cancer.

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.

The FDA amended its approval for Balversa for the treatment of patients with locally advanced or metastatic bladder cancer.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

The Food and Drug Administration has approved Padcev plus Keytruda to treat patients with locally advanced or metastatic bladder cancer.

The FDA accepted a priority review for the supplemental Biologics License Application of Opdivo with chemotherapy for untreated patients with unresectable or metastatic bladder cancer.

The FDA has granted priority review for the Padcev-Keytruda combination in untreated patients with metastatic bladder cancer, according to a news release.

Analysis of molecular subtypes of muscle-invasive bladder cancer can predict if a tumor is likely to respond to chemotherapy before surgery but is not associated with differences in survival.

Balversa improved outcomes for patients with high-risk bladder cancer, but may only work for those with a certain genetic alteration, an expert explained.